Australian Pathology: A Medical Business That Runs on Logistics

Pathology looks like a medical business and behaves like a logistics business. The clinical work of analysing a sample is largely automated and standardised; what differentiates operators is how efficiently they collect samples across a wide geography, move them to a laboratory within time and temperature constraints, process them at high utilisation and return results quickly. This article explains the economics and why the sector is structurally exposed to policy.

Why is collection centre density so important?

Because patients go where it is convenient, and convenience means near their doctor. A general practitioner writing a pathology request expects the patient to have their sample collected easily, and if the nearest collection centre belongs to one operator, that operator receives the referral by default.

This produces intense competition for sites near medical centres, and historically for arrangements with the practices themselves. Regulation restricts what pathology providers may pay for rent in medical centres precisely because unrestricted competition for those sites was inflating rents to levels that effectively purchased referral flow.

The strategic consequence is that a pathology company is really running a property and location business alongside a laboratory business. Site selection, lease negotiation and network optimisation determine sample volume, and sample volume determines whether the laboratory network is profitable.

How does Medicare funding shape the sector?

Almost entirely. Most Australian pathology is funded through Medicare benefits paid at rates set by government schedule, and providers overwhelmingly bulk bill, meaning they accept the schedule fee as full payment rather than charging patients a gap. That makes the schedule fee the effective price for most of the industry’s output.

Because that fee is set administratively rather than negotiated, the sector cannot pass through cost inflation. When wages, reagents, energy and transport costs rise while the schedule fee is indexed slowly or frozen, margins compress with no commercial response available beyond volume growth and cost reduction.

This is why efficiency is not optional in pathology. An operator facing fixed revenue per test and rising costs must continually reduce cost per test, through automation, laboratory consolidation, courier route optimisation and purchasing scale. Operators unable to do so exit or are acquired, which is the mechanism that produced the current concentrated structure.

What happened during and after the pandemic?

An enormous, temporary volume surge followed by a difficult normalisation. COVID-19 testing generated extraordinary sample volumes at attractive reimbursement, and pathology operators expanded capacity, hired staff and invested in equipment to meet demand that was assumed to persist at least partially.

When testing volumes collapsed, the cost base did not fall as quickly. Laboratory capacity built for pandemic volumes ran at lower utilisation, staff hired during the surge became surplus, and the sector faced the classic operating leverage problem in reverse — the same mechanism that makes it profitable at high volume makes it painful at low volume.

Base testing volumes also took time to recover, as routine screening and elective procedures that generate pathology demand were deferred. The sector spent the following years restructuring capacity and absorbing cost inflation without a corresponding rebate increase, which is why healthcare was a difficult sector in Australian reporting seasons through this period.

Where does growth come from?

Ageing populations and expanding test menus, principally. An older population generates more pathology episodes per person, and chronic disease management requires regular monitoring, so underlying volume grows structurally with demographics regardless of anything the operators do.

New test categories are the second driver. Genetic and genomic testing, advanced molecular diagnostics and specialised oncology testing carry higher fees and higher clinical value than routine chemistry, and shifting the mix toward them improves revenue per sample. The constraint is that new tests must be added to the Medicare schedule to be funded, which is a slow process.

International expansion is the third, and it is how the largest Australian operator has grown most. Applying the same operating model in Europe and North America, in markets with different funding structures and less consolidated competition, allows a company constrained by Australian policy to deploy capital where returns are available. It also introduces exposure to several health systems at once, each with its own reimbursement risk.

What role does technology play?

Automation has already transformed the laboratory. Modern analysers process samples continuously with minimal human handling, which is what makes the marginal cost per test so low and which is why laboratory consolidation into fewer, larger sites improves economics so reliably.

Digital pathology is the emerging change. Digitising slides allows specimens to be read remotely, which decouples the pathologist from the physical laboratory, enables workload to be distributed across a network and allows scarce subspecialist expertise to be applied wherever the sample originated. It also creates the dataset on which algorithmic assistance can be built.

Artificial intelligence in diagnostic reading is the most consequential possibility and the most uncertain in timing. Systems that pre-screen images or flag abnormalities could substantially increase throughput per specialist, which in a business defined by cost per test would be transformative. Regulatory approval, liability allocation and clinical acceptance all move slower than the technology.

How does the sector interact with general practice?

Closely and with structural tension. General practitioners generate essentially all pathology demand through requests, so the referral relationship is the commercial foundation of the industry, and the co-location of collection centres in medical centres is the physical expression of it.

That relationship has been regulated precisely because it was distorting. Pathology providers competing for medical centre tenancies bid rents well above market value, which effectively purchased referral flow and inflated costs across the system. Rules limiting permissible rent to market value were introduced to break that dynamic, and enforcement has been an ongoing issue.

The clinical dimension matters as well. Pathology requesting patterns vary substantially between practitioners, and both over-requesting and under-requesting carry costs – unnecessary tests consume public funding and generate incidental findings, while missed tests delay diagnosis. Efforts to standardise requesting are clinically motivated and have direct commercial consequences for volume-dependent providers.

What does consolidation mean for patients?

Mixed outcomes that are easy to characterise unfairly in either direction. Scale delivers genuine benefits: broader test menus, faster turnaround through automated high-volume laboratories, better quality systems, and access to subspecialist expertise that a small independent laboratory could not employ.

The costs are less visible. Laboratory consolidation means specimens travel further, which extends turnaround for some tests and creates single points of failure – a processing disruption at a central laboratory affects a whole region rather than one suburb. Local pathologist relationships with referring doctors also weaken as the network centralises.

The pricing effect is muted by the funding model, which is the important qualifier. In most concentrated industries consolidation raises prices; in Australian pathology the government sets the fee, so consolidation shows up as margin for the operator rather than cost to the patient. That is why competition concerns in this sector focus on referral arrangements and market access rather than on pricing.

A closing observation on why this sector is worth understanding beyond healthcare. Pathology is one of the clearest examples in the Australian economy of a business where the customer does not choose the supplier, the supplier does not set the price, and the party that does choose – the referring doctor – pays nothing. Every unusual feature of the industry, from collection centre rents to consolidation to the intensity of the funding debate, follows from that separation of choosing, paying and receiving. Any market with the same structure will produce similar behaviour.

What is the outlook for the sector?

Volume growth from demographics against margin pressure from funding. An ageing population generates more testing episodes per person, and chronic disease management requires ongoing monitoring, so underlying demand grows structurally regardless of policy. That is the reliable part.

The unreliable part is whether reimbursement keeps pace with cost. Wages, energy, reagents and transport have all risen substantially, and if the schedule fee is indexed below cost inflation, operators must find efficiency gains every year simply to hold margin. Several years of that produces the sector consolidation and cost programmes that have characterised recent reporting seasons.

The structural answer for the largest operators has been international diversification, applying the same operating model in markets where funding is set differently. That reduces exposure to any single government’s decisions and introduces exposure to several, which is genuine diversification rather than risk elimination.

For anyone assessing a listed pathology or imaging operator, the single most informative disclosure is revenue per test alongside test volume growth, reported separately. Volume growth reflects demographics and market share; revenue per test reflects the mix shift toward higher-value tests against the effect of schedule fee indexation. A business growing volume while revenue per test falls is working harder for the same result, and that pattern precedes margin compression by several periods.

Frequently Asked Questions